BioWorld

May 29, 2003

Compound Secures $12M Series A Round To Drive Adzyme Research

Compound Therapeutics Inc. has hit the ground running after closing a $12 million Series A round of financing.(BioWorld Today) Read More

Vivus Gets $17.5M In Private Placement To Push Products

Stem Cells Still Divisive; Senate Bill To Require Pediatric Trials

Awaiting Cialis Decision, ICOS Files $150M Shelf Registration

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 15, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...